Abstract
The Major Histocompatibility Complex Class II locus is the primary genetic linkage to autoimmune diseases. Susceptibility to each such disease is linked to different alleles, with a few alleles showing also dominant protection. The design of vaccines for autoimmune diseases is a long sought-after goal. As knowledge about the pathogenesis of these diseases has increased, the tools for such an approach have of necessity been refined. We review below the structural essence of MHC II-linked autoimmune diseases which centers on the binding of antigenic peptides to the disease-linked MHC II proteins, and the consequent activation of cognate TCRs from pathogenic CD4+ T cells. The state of affairs in two organ-specific autoimmune diseases, type 1 diabetes, celiac disease are covered, including attempts to treat these via antigen-specific MHC II-guided measures. We offer a couple of testable suggestions as to how this approach could be improved.
Keywords: APL, autoimmunity, HLA, MHC, vaccines
Current Pharmaceutical Design
Title: Use of MHC II Structural Features in the Design of Vaccines for Organ-Specific Autoimmune Diseases
Volume: 15 Issue: 28
Author(s): Antonis K. Moustakas and George K. Papadopoulos
Affiliation:
Keywords: APL, autoimmunity, HLA, MHC, vaccines
Abstract: The Major Histocompatibility Complex Class II locus is the primary genetic linkage to autoimmune diseases. Susceptibility to each such disease is linked to different alleles, with a few alleles showing also dominant protection. The design of vaccines for autoimmune diseases is a long sought-after goal. As knowledge about the pathogenesis of these diseases has increased, the tools for such an approach have of necessity been refined. We review below the structural essence of MHC II-linked autoimmune diseases which centers on the binding of antigenic peptides to the disease-linked MHC II proteins, and the consequent activation of cognate TCRs from pathogenic CD4+ T cells. The state of affairs in two organ-specific autoimmune diseases, type 1 diabetes, celiac disease are covered, including attempts to treat these via antigen-specific MHC II-guided measures. We offer a couple of testable suggestions as to how this approach could be improved.
Export Options
About this article
Cite this article as:
Moustakas K. Antonis and Papadopoulos K. George, Use of MHC II Structural Features in the Design of Vaccines for Organ-Specific Autoimmune Diseases, Current Pharmaceutical Design 2009; 15 (28) . https://dx.doi.org/10.2174/138161209789105117
DOI https://dx.doi.org/10.2174/138161209789105117 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Utility and Medicinal Chemistry of Cathepsin C Inhibitors
Current Topics in Medicinal Chemistry Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design Structure, Function and Biological Relevance of Prolyl Oligopeptidase
Current Protein & Peptide Science The TGF-β 1/Foxp3 Regulatory Axis in Immune Self-Tolerance: Implications for Health and Disease
Inflammation & Allergy - Drug Targets (Discontinued) Role of the Immune System in Autism Spectrum Disorders (ASD)
CNS & Neurological Disorders - Drug Targets Gene Therapy for Immunologic Tolerance: Using Bone Marrow-Derived Cells to Treat Autoimmunity and Hemophilia
Current Stem Cell Research & Therapy Sex Steroids in Autoimmune Diseases
Current Topics in Medicinal Chemistry Vitamin D : Autoimmunity and Gender
Current Medicinal Chemistry Molecular Genetics and Epidemiology of Japanese Type 1 Diabetes
Current Pharmacogenomics Interleukin-7: a key Mediator in T Cell-driven Autoimmunity, Inflammation, and Tissue Destruction
Current Pharmaceutical Design Pattern Recognition Receptors and Control of Innate Immunity: Role of Nucleic Acids
Current Pharmaceutical Biotechnology Fc Receptors as Potential Targets for the Treatment of Allergy, Autoimmune Disease and Cancer
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Long and Winding Road: Searching for Non-MHC Psoriasis Susceptibility Loci
Current Genomics Ganglioside Mimicry as a Cause of Guillain-Barre Syndrome
CNS & Neurological Disorders - Drug Targets Reactive Oxygen Species in the Initiation of IL-4 Driven Autoimmunity as a Potential Therapeutic Target
Current Pharmaceutical Design The Janus Face of CD4+CD25+ Regulatory T Cells in Cancer and Autoimmunity
Current Medicinal Chemistry Synthetic Peptides in the Diagnosis of Systemic Autoimmune Diseases
Current Protein & Peptide Science Tumor Necrosis Factor Inhibitors from Poxviruses with An Emphasis on Tanapoxvirus-2L Protein
Recent Patents on DNA & Gene Sequences Mediators of Tyrosine Phosphorylation in Innate Immunity: From Host Defense to Inflammation onto Oncogenesis
Current Signal Transduction Therapy Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?
Current Clinical Pharmacology